Literature DB >> 2269286

Structural characterization of a recombinant CD4-IgG hybrid molecule.

R J Harris1, K L Wagner, M W Spellman.   

Abstract

CD4-IgG is a homodimer of a hybrid polypeptide consisting of the two amino-terminal domains (residues 1-180) of human CD4 fused to the hinge region and the second and third constant-sequence (CH2 and CH3) Fc domains (residues 216-441) of human immunoglobulin G (IgG-1). This antibody-like molecule, termed an immunoadhesin, was produced in an effort to combine the binding specificity of CD4 with several potentially desirable properties of IgG molecules [Capon et al. (1989) Nature 337, 525-531]. The structural characteristics of the molecule have been evaluated to demonstrate that CD4-IgG has the same features as the N-terminal region of soluble CD4, while retaining those expected for the Fc portion of human IgG. Identification of peptides recovered from the tryptic map confirmed 98.8% of the expected structure of CD4-IgG. The detection of glucosamine in peptides containing Asn257 and the retention time shift of this tryptic peptide after deglycosylation confirmed the presence of Asn-linked oligosaccharides at this position. Four pairs of intrachain and two interchain disulfide bonds were also established.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2269286     DOI: 10.1111/j.1432-1033.1990.tb15660.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping.

Authors:  D J Kroon; A Baldwin-Ferro; P Lalan
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Authors:  Lusine H Demirkhanyan; Mariana Marin; Sergi Padilla-Parra; Changyou Zhan; Kosuke Miyauchi; Maikha Jean-Baptiste; Gennadiy Novitskiy; Wuyuan Lu; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

4.  Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation.

Authors:  Aemro Kassa; Andrés Finzi; Marie Pancera; Joel R Courter; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

5.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

6.  Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex.

Authors:  T L Hodges; J O Kahn; L D Kaplan; J E Groopman; P A Volberding; A J Amman; C J Arri; L M Bouvier; J Mordenti; A E Izu
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

7.  Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

Authors:  Ewald T J van den Bremer; Frank J Beurskens; Marleen Voorhorst; Patrick J Engelberts; Rob N de Jong; Burt G van der Boom; Erika M Cook; Margaret A Lindorfer; Ronald P Taylor; Patrick Hc van Berkel; Paul Whi Parren
Journal:  MAbs       Date:  2015       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.